ROCHE Pharmaceuticals is
reportedly seeking financing as
part of a potential offer to purchase
Alexion Pharmaceuticals, according
to news service Bloomberg.
Shares in Alexion soared
almost 24% on the news, and
if the deal proceeds it would
see Roche take ownership of
Alexion’s only marketed product,
Soliris, which is an orphan drug
approved by the US FDA for the
treatment of paroxysmal nocturnal
haemoglobinuria and atypical
haemolytic uremic syndrome.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jul 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.